
==== Front
Discov Oncol
Discov Oncol
Discover Oncology
2730-6011
Springer US New York

39259333
1330
10.1007/s12672-024-01330-4
Review
KIF18B: an important role in signaling pathways and a potential resistant target in tumor development
Chen Shicheng 1
Yu Bo 1
DU Guo TU 2
Huang Tian Yu 2
Zhang Neng energy20170118@hotmail.com

2
Fu Ni 18985601188@163.com

1
1 grid.413390.c 0000 0004 1757 6938 Department of Urology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, 563000 P. R. China
2 https://ror.org/00g5b0g93 grid.417409.f 0000 0001 0240 6969 Department of Urology, The Affiliated Hospital of Zunyi Medical University, Zunyi, 563000 P. R. China
11 9 2024
11 9 2024
12 2024
15 43022 5 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
KIF18B is a key member of the kinesin-8 family, involved in regulating various physiological processes such as microtubule length, spindle assembly, and chromosome alignment. This article briefly introduces the structure and physiological functions of KIF18B, examines its role in malignant tumors, and the associated carcinogenic signaling pathways such as PI3K/AKT, Wnt/β-catenin, and mTOR pathways. Research indicates that the upregulation of KIF18B enhances tumor malignancy and resistance to radiotherapy and chemotherapy. KIF18B could become a new target for anticancer drugs, offering significant potential for the treatment of malignant tumors and reducing chemotherapy resistance.

Keywords

Kinesins family
KIF18B
MT
Signaling pathways
Tumorigenesis
Plan of Science and Technology of Zunyi2022-403 Guizhou Provincial Health Commissiongzwkj2023-374 2024GZWJKJXM0704 issue-copyright-statement© Springer Science+Business Media, LLC 2024
==== Body
pmcIntroduction

In 1985, Vale et al. identified a novel force-producing molecule in the axons of squid, which they named kinesin [1]. Researchers have now identified a kinesin superfamily that includes 45 different kinesins, each featuring a head (motor) domain, a stalk (coiled-coil, CC) domain, and a tail domain [2]. These proteins are classified into 14 families (kinesin-1 to kinesin-14) [3], mainly functioning in the cellular microtubule system by transporting organelles, protein complexes, and mRNA to specific destinations through ATP consumption [4, 5], Moreover, these proteins are critical in the processes of chromosome movement and spindle assembly [6]. However, these molecules exhibit distinct functions. For example, KIF2A is dispensable in embryonic neurogenesis, yet essential for neuronal maturation, connectivity, and maintenance in postnatal stages. Its deficiency results in early-onset neurodegeneration [7]; Moreover, mutations in KIF5A are associated with familial amyotrophic lateral sclerosis (ALS) [8, 9]; KIF13B and KIF5B can collaborate to promote the transport of secretory vesicles [10].

Kinesin-8 is commonly recognized as a microtubule (MT) depolymerase, with its main role being the regulation of microtubule lengths and chromosome movements during animal mitosis [11]. It comprises two subfamilies, KIF18 and KIF19 [5], and is structurally characterized by a specific helical neck region [12]. KIF18B collaborates with MCAK to regulate microtubule depolymerization [13, 14], with KIF18B impacting microtubule length, spindle assembly, and chromosome arrangement by delivering cargo to the microtubule’s plus-end [15].

The link between KIF18B and tumors has emerged as a focal point of study in recent years. Increasing research indicates that KIF18B is overexpressed in various cancers of the respiratory, urinary, and digestive systems, and it promotes tumor proliferation. Data from survival analyses indicate that high expression of KIF18B is closely linked to poor outcomes [16–20]. A pan-cancer study indicates that KIF18B not only participates in cell cycle regulation but is also associated with tumor immune infiltration and can serve as a prognostic biomarker [21]. In this review, we will focus on discussing the functions of KIF18B in cancer and its mechanisms of action.

Structure and regulation of KIF18B

The human KIF18B gene is located in the chromosome 17q21.31 region, encoding a protein with a molecular weight of 94kD. Structurally, KIF18B is composed of an N-terminal motor domain, a positively charged neck structural domain, and a stalk-tail domain, which includes one SIP sequence and three IP sequences (containing one SIP sequence and three IP sequences) [12, 22] (Figure 1). During interphase, KIF18B is predominantly expressed inside the cell nucleus; however, as mitosis begins, KIF18B spreads to the cell cortex and into the microtubules and adjacent areas, thereby strengthening microtubule dynamics and facilitating the reorganization of the cytoskeleton during mitosis [14, 23]. Regarding its functions, KIF18B not only adjusts microtubule length but also aids in the repair of DNA double-strand breaks [24]and assist in spindle positioning and helps in the positioning of the spindle [23].Fig. 1 The structure of KIF18B. A KIF18B protein structure chart (source: UniProt protein database). B Schematic diagram of KIF18B structure: Comprising an N-terminal motor domain, a positively charged neck domain, and a stalk-tail domain, which includes one SIP sequence and three IP sequences

The expression of KIF18B is specific to certain tissues and is regulated by the cell cycle [14]. Transport proteins and transcription factors can induce the transcriptional expression of KIF18B [15, 25]. FOXM1, a transcription factor that controls the progression of the cell cycle, is overexpressed in most human cancers [26]. Research by Ji and others has demonstrated that KIF18B can be transcriptionally activated as a direct downstream target of FOXM1 [15].Additional evidence suggests that knockdown of KIF18B can lead to cell cycle arrest in various cancer cells, although the phases of arrest may differ Further experiments have confirmed that knockdown of KIF18B causes cell cycle arrest in various cancer cells, with the phase of arrest varying [20, 27, 28], indicating that KIF18B’s impact on the cell cycle varies among different cancers. Regrettably, studies on the upstream regulators of KIF18B are still somewhat limited. Identifying the molecules or external stimuli that can activate KIF18B’s transcriptional expression requires additional research.

In addition, KIF18B is involved in the activation and regulation of protein kinases and signaling molecules. Gamma-actin (γ-actin), as a binding partner of KIF18B, collaboratively regulates lysosome positioning, facilitates the transport of mTOR complex 1 (mTORC1) to lysosomal membranes, and prevents p70 S6K from entering lysosomes for degradation, ultimately enhancing mTORC1 signaling [15]. Xie and colleagues’ research indicates that KIF18B’s regulatory effect on mTORC1 depends on the activation of CDCA8 [16]. This indicates that there are various pathways through which KIF18B regulates mTORC1. The influence of KIF18B on tumor cell progression is closely linked to the activation of several signaling pathways. For instance, in prostate, breast, and lung cancers, KIF18B’s regulation of tumor cell proliferation is accompanied by the activation of the AKT pathway [18, 29, 30], while in hepatocellular carcinoma, cervical cancer, and bladder urothelial cancer, KIF18B’s control over tumor cell viability involves the Wnt/β-catenin pathway [28, 31, 32]. Thus, the regulatory function of KIF18B in tumor cells relies on the cooperative effects of multiple signaling pathways, and clarifying KIF18B’s direct downstream targets and mechanisms will aid in a deeper understanding of tumor progression mechanisms.

Physiological functions of KIF18B

Previous studies have reported that KIF18B can promote chromosome congression and restrict microtubule length during mitosis [33]. Similar to other motor proteins, KIF18B employs its C-terminal non-motor microtubule-binding domain to identify and accumulate at the ends of microtubules in vitro [34]. In contrast to the effects of knocking down KIF18A, the knockdown of KIF18B in PtK cells—a cell type particularly suitable for microtubule (MT) array imaging—resulted in reduced microtubule growth speed and maintained the microtubules in a state of continuous growth. This suggests that members of the kinesin-8 superfamily can have divergent impacts on microtubule dynamics [35]. As KIF18B moves along microtubules away from areas of kinase activity, it undergoes dephosphorylation by cytoplasmic phosphatases. This dephosphorylation enables KIF18B to stay longer at microtubule tips, resulting in its accumulation at the plus-ends of elongated astral microtubules. This process leads to microtubule instability, which helps ensure correct spindle positioning [23]. Following this, additional research was carried out to delve deeper into the role of KIF18B in microtubules and spindles. In KIF18B-knockdown cell lines, the localization of MCAK at microtubule plus-ends was compromised, interrupting EB1 interactions, obstructing the accumulation of KIF18B at microtubule plus-ends, and inhibiting its capacity to control microtubule lengths on monopolar spindles. Subsequent studies confirmed that KIF18B transports MCAK to microtubule plus-ends by interacting with the N-terminus of MCAK and EB3, thereby promoting microtubule catastrophe [25, 36].

Furthermore, Shin et al. found that KIF18B exhibits two different modes of movement: directed motion and predominantly diffusive motion, which are regulated by its tail structure and mainly powered by ATP hydrolysis [33]. However, McHugh and his team’s experiments show that KIF18B is a highly processive motor. It approaches the plus-end of microtubules via directed movement instead of diffusion and negatively regulates microtubule dynamics by encouraging catastrophic events [23]. This variation might result from the N-terminal GFP tag inhibiting KIF18B’s movement characteristics or from differences in cell types affecting its diffusion.

KIF18B in tumorigenesis and related signaling pathways

Adenocarcinoma of the lung

Lung cancer is one of the most common cancers worldwide and a leading cause of cancer incidence and mortality in developed countries, with over one million deaths annually due to the disease [37, 38]. Adenocarcinoma of the lung (ADC) constitutes 40% of new lung cancer cases and is the most prevalent type among non-smokers [39]. Ji and his team, through database analysis, determined that KIF18B is significantly overexpressed in lung adenocarcinoma samples compared to normal tissues, with high levels closely correlating with poor patient outcomes. Cellular experiments have shown that reducing KIF18B suppresses the malignant proliferation of lung cancer cells. In this process, the reduction of KIF18B notably decreased the expression of Rac1-GTP, a critical marker for tumor migration and invasion. Moreover, the phosphorylation levels of AKT and mTOR were diminished following the knockdown of KIF18B, suggesting that this intervention could inhibit the proliferation, migration, and invasion of lung adenocarcinoma cells by controlling the expression of the Rac1-mediated AKT/mTOR signaling pathway [30]. Later retrospective clinical research also verified that a poor prognosis in lung adenocarcinoma patients correlates with high KIF18B expression [40, 41]. Functional analyses of KIF18B indicate that it could regulate basic physiological processes in lung adenocarcinoma cells, including cell cycle control, DNA replication, and DNA repair [27, 40]. But these predictions still need to be experimentally validated.

Bladder cancer

Bladder cancer (BCa) is the most prevalent malignant tumor in the urinary tract and ranks as the fourth most common malignancy among men, closely associated with factors such as age, gender, and smoking habits [42, 43]. Cancer stem cells (CSCs) constitute a subgroup of tumor cells that are capable of driving tumor initiation and potentially causing relapse [44]. Recently, through transcriptomic analysis, Pan and colleagues found that KIF18B is upregulated in bladder cancer, possibly playing a crucial role in sustaining bladder cancer stem cells [45]. Further research has revealed that KIF18B plays a critical role in bladder cancer, not only enhancing cell survival, proliferation, and invasion but also activating signaling molecules such as β-catenin. β-catenin, a downstream molecule of the Wnt signaling pathway, can initiate cancer development and progression upon activation [46]. Furthermore, miRNA-139-3p binds to the 3’UTR of KIF18B mRNA, negatively regulating KIF18B; concurrently, overexpression of KIF18B reverses the inhibitory effect of miRNA-139-3p on bladder cancer cells. This indicates that the miRNA-139-3p/KIF18B axis might suppress the malignant effects of BUC by modulating the Wnt/β-catenin signaling pathway, thereby offering a potential therapeutic target for BUC patients [31]. Yet, there are currently no studies reporting whether KIF18B can activate stem cell-related molecules such as SOX2 and KLF4, and affect the malignant proliferation of bladder cancer cells.

Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, typically developing from chronic liver diseases or cirrhosis, with a high mortality rate [47, 48]. Early stages of hepatocellular carcinoma are managed with liver resection and various surgical interventions, while advanced stages may be treated with chemotherapy, immunotherapy, and oncolytic viruses [49]. Yang and his team found that KIF18B is frequently overexpressed in patients with liver cancer, and knocking it down substantially reduces liver cancer cell proliferation, migration, and invasion. The knockdown of KIF18B significantly reduces the activity of the Wnt/β-Catenin pathway, while treatment with the Wnt/β-Catenin pathway activator lithium chloride (LiCl) can reverse the anti-tumor effect of KIF18B knockdown, suggesting that the Wnt/β-Catenin pathway may serve as its principal effector pathway [50]. Another research indicated that high levels of KIF18B significantly correlate with shorter overall and disease-free survival in HCC patients, marking it as an independent indicator of poor prognosis [51].

Gene co-expression analysis has shown a close association between KIF18B expression and immune cell infiltration [52]. Further experiments show that KIF18B is highly expressed in two immune subtypes, C1 (wound healing) and C2 (INF-r dominant), and knockdown of KIF18B inhibits EMT and reduces the invasiveness and migration of HCC cells. These findings have been validated in in vivo experiments, but the specific mechanisms by which KIF18B regulates EMT still need further study [21]. Similar research demonstrates that among immune cells, activated regulatory T cells (Tregs) exhibit the strongest positive correlation with KIF18B (R = 0.631). Groups with high KIF18B expression show significantly increased infiltration of Tregs and a notable decrease in the infiltration of CD8 Tcells and macrophages [53]. Additionally, KIF18B functions in HCC via mTOR complex 1 (mTORC1). mTOR acts as a crucial regulator of immune system cell differentiation and function. In cancer cells, disrupted mTOR signaling alters the tumor microenvironment, impacting tumor immunity and potentially fostering cancer progression [54, 55]. KIF18B expression positively correlates with the mTORC1 signaling pathway in HCC tissues and is linked with HCC recurrence. Actin gamma 1 (γ-Actin), a binding partner of KIF18B. It also facilitates the transfer of mTORC1 to the lysosomal membrane and prevents the degradation of p70 S6K in lysosomes, thereby enhancing mTORC1 signaling [15]. Thus, an essential inquiry is whether the knockdown of KIF18B could activate immune cells, subsequently suppressing the malignant proliferation of cancer cells.

Breast cancer

Breast cancer (BC) is the deadliest cancer among women and ranks as the second leading cause of cancer-related deaths after lung cancer [56]. Breast cancer can be categorized into three main types: hormone receptor (HR) positive, HER2 negative, HER2 positive, and triple-negative breast cancer (TNBC) [57]. Recently, Li and others have determined through bioinformatics analysis that KIF18B is upregulated in breast cancer and significantly correlates with relapse-free survival (RFS) and distant metastasis-free survival (DMFS) in patients [58]. Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells acquire mesenchymal characteristics. In cancer, EMT is associated with tumorigenesis, cancer stemness, metastasis, and resistance to therapy [59, 60]. Analysis from RNA sequencing (RNA-seq) suggests that KIF18B is linked to the stemness of breast cancer tumors [61]. KIF18B directly targets thyroid hormone receptor-interacting protein 13 (TRIP13) and increases the expression level of TRIP13. Knockdown of KIF18B significantly reduces TRIP13 expression, which suppresses proliferation, invasion, and EMT in breast cancer cells, and decreases the expression of matrix metalloproteinases (MMP2, MMP9), When TRIP13 is overexpressed, it counteracts the inhibitory effects of KIF18B knockdown on the malignant progression of breast cancer cells [32]. Additionally, knocking down KIF18B significantly enhanced the chemotherapy sensitivity of breast cancer cells to doxorubicin, and overexpressing KIF18B activate the Wnt/β-catenin signaling pathway, while the use of MK-2206 (an AKT inhibitor) negates the activation of the Wnt/β-catenin pathway induced by KIF18B overexpression [29]. Therefore, KIF18B may promote tumor stemness by influencing EMT. Consequently, in malignant tumors such as BC, developing drugs targeting KIF18B could help formulate new strategies to slow cancer progression.

Gastric cancer

Gastric cancer (GC), defined as a primary epithelial malignancy of the stomach, involves various risk factors and is a complex, heterogeneous disease, ranking among the most common malignancies globally [62, 63]. The overall survival rate of gastric cancer is extremely low, largely due to its typical late-stage diagnosis [64]. Research has indicated that KIF18B is linked to the prognosis of patients with gastric adenocarcinoma and may serve as a potential therapeutic target for gastric cancer [65–67]. Further experiments have shown that KIF18B can promote the proliferation, migration, and invasion of gastric cancer cells, while silencing KIF18B causes cell cycle arrest at the G0-G1 phase in gastric cancer cells [17], consistent with findings in other cancers [27, 40]. This suggests that KIF18B is closely related to cell cycle regulation and may facilitate malignant progression by disrupting normal cell cycle functions. Multiple studies have also pointed out that KIF18B is critical in maintaining the stem cell-like properties of gastric cancer and influences the features of cancer stem cells (CSCs) in the disease [65, 68, 69]. Nonetheless, these discoveries require further experimental confirmation.

Other cancers

Beyond the previously mentioned cancers, new evidence has highlighted the abnormal expression and oncogenic potential of KIF18B in a range of malignancies, such as esophageal cancer (EC) [16], prostate cancer (Pca) [18], renal cell carcinoma (RCC) [70], colorectal cancer (CRC) [19], pancreatic ductal adenocarcinoma (PDAC) [20], soft tissue sarcoma (STS) [71], melanoma (MM) [72], squamous cell carcinoma of the skin (SCC) [73] and cervical cancer (CC) [28]. For example, in EC, the abnormal expression of KIF18B enhances cellular activity by increasing levels of CDK4 and Cyclin D3, accelerating the cell cycle, and promotes cell migration and invasion by reducing E-cadherin levels and increasing vimentin and N-cadherin levels in ESCC cells. However, the specific mechanisms by which KIF18B regulates EMT still require further elucidation [16]. Initial studies linked KIF18B with poorer overall survival in prostate cancer patients [74] and subsequent research showed that KIF18B’s role in advancing prostate cancer malignancy is associated with the activation of the PI3K-AKT-mTOR signaling pathway, although the precise regulatory mechanisms still need deeper exploration [18]. Recently, Liu and others found that silencing KIF18B or using T09 (a radiosensitizer targeting KIF18B) significantly increased the radiosensitivity of STS cells, delayed tumor growth in subcutaneous and orthotopic xenograft models, and prolonged the survival of mice [71]. Similarly, in CRC, KIF18B interacts with SP1 to induce overexpression of PARPBP, maintaining oxaliplatin resistance in oxaliplatin-resistant CRC (OR-CRC) cells [19]. This indicates that KIF18B might act as a novel target for anticancer drugs, offering considerable potential in cancer treatment and alleviating chemotherapy resistance. The roles and mechanisms of action of KIF18B across various tumors are detailed in Table 1.

Table 1 The role and mechanism of KIF18B in diverse cancers

Type of Cancer	Cell or animals	Mechanism	Conclusion	Associated With patient prognosis	Reference	
ADC	A549 cells	Activating AKT/mTOR pathway	Knockdown of KIF18B significantly inhibits the proliferation, migration, and invasion of ADC cells.	High expression is associated with poorer prognosis.	[30, 40, 41]	
BCa	T24 and J82 cells	Activating Wnt/β-catenin pathway	Promotes survival, proliferation, and invasion of BCa cells.	NR	[31]	
HCC	HepG2,Huh7,MHCC97H, HHCCLM3,Hep3B cells and nude mice	Activating Wnt/β-catenin pathway and mTOR pathway	Knockdown of KIF18B significantly inhibits proliferation, migration, invasion, and EMT in HCC cells, while simultaneously promoting apoptosis.	High expression is associated with poorer prognosis.	[15, 51, 21]	
BC	MDA-MB231 T47D cells and nude mice.	Activating Akt/GSK-3β/β-catenin pathway	Knockdown of KIF18B significantly inhibits the proliferation, invasion, and EMT of BC cells, and enhances the chemosensitivity of paclitaxel.	High expression is associated with poorer prognosis.	[29, 32, 58]	
GC	SNU-1	NR	Promotes proliferation, migration, and invasion of GC cells.	High expression is associated with poorer prognosis.	[17, 65, 66]	
EC	EC9706

KYSE220

	Activating CDCA8/mTORC1 pathway	Promotes migration, invasion, and EMT of ESCC cells.	High expression is associated with poorer prognosis.	[16]	
Pca	DU145 PC3 cells and mice	Activating PI3K/AKT/ mTOR pathway	Promotes proliferation, migration, and invasion of Pca cells.	High expression is associated with poorer prognosis.	[18]	
STS	MNNG/HOS cells and mice	NR	Silencing KIF18B can enhance the radiosensitivity of STS.	High expression is associated with poorer prognosis.	[71]	
CRC	HCT116L cells	inducing PARPBP expression	Increases the resistance of colorectal cancer to oxaliplatin	High expression is associated with poorer prognosis.	[19]	
PDAC	PANC1 BxPC3 cells and mice	transcriptionally activating CDCA8	Promotes PDAC proliferation	High expression is associated with poorer prognosis.	[20]	
CC	Hela cells and mice	Activating Wnt/β-catenin pathway	Promotes proliferation, migration, and invasion of CC cells.	High expression is associated with poorer prognosis.	[28]	
NR no reported

KIF18B in cancer therapy

KIF18B in chemoresistance

Doxorubicin (DOX) is a chemotherapy drug widely used to treat various cancers [75]. It interferes with numerous biological processes, including histone eviction, excessive ceramide production, DNA adduct formation, reactive oxygen species generation, and regulation of Ca2 + and iron homeostasis [76]. DOX serves as a primary chemotherapeutic agent for breast cancer, targeting cancer cells by inducing DNA cross-linking damage [77]. In breast cancer, KIF18B may facilitates tumor progression by regulating the Akt/GSK-3β/β-catenin signaling pathway [29]. The AKT pathway is one of the most commonly activated pathways in breast cancer [78]. Using an AKT inhibitor (MK-2206) can counteract the malignant proliferation of breast cancer cells induced by KIF18B overexpression. Furthermore, research shows that reducing KIF18B expression can enhance the sensitivity of breast cancer cells to DOX and significantly reduce their malignant characteristics [29]. Thus, in the context of breast cancer, a combination therapy involving small molecule drugs targeting KIF18B along with AKT inhibitors or DOX could offer a promising treatment avenue.

Oxaliplatin (OXA), a commonly used platinum-based chemotherapy drug for colorectal cancer [79], however, it is estimated that 50% of patients eventually develop acquired resistance and cease responding to the treatment [80]. PARPBP, also known as PARI (PCNA-associated recombination inhibitor), is significantly upregulated in oxaliplatin-resistant colorectal cancer (OR-CRC) cells, with its expression positively correlating with KIF18B levels. Reduction in PARPBP expression can decrease drug resistance in OR-CRC cells. Overexpression of KIF18B increases both mRNA and protein levels of PARPBP in OR-CRC cells, while knockdown of KIF18B reduces PARPBP expression in these cells. Further experiments show that KIF18b can bind to SP1 and competitively inhibit the interaction between SP1 and DNMT3b, thus hindering the methylation of the PARPBP promoter, activating PARPBP transcription, and subsequently increasing the resistance of OR-CRC cells, which affects patient prognosis [19].

Beyond the specified chemotherapeutic agents, diffuse large B-cell lymphoma (DLBCL) cells with KIF18B knocked out exhibit reduced cell cycle arrest and apoptosis, resulting in enhanced tolerance to vincristine [81]. Another study on gastric cancer showed that in vitro, downregulating KIF18B enhances the chemotherapy sensitivity of gastric cancer cells to cisplatin (CDDP) and 5-fluorouracil (5-FU), and reduces cell proliferation, migration, and invasiveness, with similar results obtained in a xenograft tumor model in nude mice [82]. In summary, targeting KIF18B may enhance the efficacy of cancer chemotherapy, a hypothesis that requires further experimental validation.

KIF18B in radiotherapy

Radiation therapy (RT) is a key modalities in cancer treatment, with over 70% of cancer patients undergoing RT during their treatment course [83]; Additionally, RT serves as a primary method for treating sarcoma [84]. According to the Genomic Drug Sensitivity Database (GDSC), T09 was identified as a KIF18B-sensitive drug. Silencing KIF18B or using the KIF18B-sensitive drug T09 significantly enhanced the radiosensitivity of sarcoma cells, delayed tumor growth in subcutaneous and orthotopic xenograft models, and extended the survival time of mice. Research indicates that sarcomas with low KIF18B expression may benefit from radiotherapy [71].

Conclusion and future prospects

This review comprehensively describes the critical roles of KIF18B in physiological processes and its potential mechanisms for regulating the malignant progression of tumors, examines its expression across various cancer types, explores its carcinogenic potential, and evaluates its potential clinical implications. KIF18B gene expression is markedly elevated in a variety of cancers compared to benign tissues The increased expression of KIF18B impacts several cellular activities, such as cell proliferation, migration, invasion, cell cycle regulation, and resistance to treatment. These data also suggest that the expression of the KIF18B gene or protein can serve as a prognostic marker for patients. However, these studies are mainly conducted at the cellular and animal levels and face limitations, including inadequate clinical sample sizes and limited clinical relevance.

While high expression of KIF18B in various cancers has been noted, the specific molecular mechanisms driving its expression remain unclear. Besides disrupting the cell cycle of tumors, it is still uncertain whether KIF18B also affects the stemness of tumors. Although it is established that knockdown of KIF18B reduces radiosensitivity in sarcomas, whether this effect is similar in other types of cancer remains uncertain. On the other hand, we have outlined the role of KIF18B in promoting the development of multiple tumors and its involvement in various signaling pathways, highlighting its significant potential for clinical applications. Current research on structural mutations of KIF18B and its regulatory factors is limited. Beyond database analysis, can KIF18B gene mutations be associated with clinical genetic testing? Additionally, it is known that KIF18B is involved in the resistance mechanisms of chemotherapy drugs such as DOX and OXA, but the specific mechanisms of action remain unclear. Further research should focus on the mechanisms and specific targets of KIF18B in resistance processes and explore whether KIF18B can be combined with various chemotherapy drugs to enhance anticancer effects. Regrettably, apart from T09, no other small molecule drugs specific to KIF18B have been reported, nor have they undergone clinical trials. Therefore, it is particularly urgent to develop targeted drugs against KIF18B and to advance their clinical trials.

KIF18B is closely associated with tumor progression, invasion, metastasis, and poor prognosis. Numerous studies demonstrate that KIF2C is involved in several cellular signaling pathways, including the AKT/mTOR, Wnt/β-catenin, and PI3K pathways, as summarized in Fig. 2. Thus, KIF18B plays a role in multiple aspects of tumorigenesis, and its regulatory functions may offer novel and effective targets for cancer treatment.Fig. 2 KIF18B is involved in the signaling pathways related to tumor occurrence and the regulatory effects of microRNAs and transcription factors on KIF18B. In prostate, breast and lung cancers, the regulation of tumor cell proliferation by KIF18B is accompanied by activation of the AKT pathway. The regulation of the life activities of cancer cells in hepatocellular carcinoma, cervical cancer, bladder urothelial carcinoma and other cancers by KIF18B requires the involvement of the Wnt/β-catenin pathway. γ-actin (γ-actin) as a binding partner of KIF18B, cooperatively regulates lysosome positioning, promotes the transport of rapamycin complex 1 (mTORC1) to the lysosomal membrane and prevents p70 S6K from entering lysosomes for degradation. In CRC, KIF18B interacts with SP1 to induce overexpression of PARPBP, maintaining oxaliplatin resistance in OR-CRC cells

Acknowledgements

There is no acknowledgment.

Author contributions

C and Y drafted the manuscript. D and H collected and analyze data. F and Z checked the figure and table and revised the manuscript.All authors reviewed the manuscript.

Funding

This study was supported by the grants from the plan of Science and Technology of Zunyi (Grant no.: 2022-403) and the Guizhou Provincial Health Commission (Grant no.: gzwkj2023-374, 2024GZWJKJXM0704).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shicheng Chen and Bo Yu have contributed equally to this work.
==== Refs
References

1. Vale RD Reese TS Sheetz MP Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility Cell 1985 42 1 39 50 10.1016/S0092-8674(85)80099-4 3926325
Vale RD, Reese TS, Sheetz MP. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell. 1985;42(1):39–50.3926325 10.1016/S0092-8674(85)80099-4
2. Lucanus AJ Yip GW Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics Oncogene 2018 37 7 833 8 10.1038/onc.2017.406 29059174
Lucanus AJ, Yip GW. Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics. Oncogene. 2018;37(7):833–8.29059174 10.1038/onc.2017.406
3. Lawrence CJ Dawe RK Christie KR Cleveland DW Dawson SC Endow SA Goldstein LS Goodson HV Hirokawa N Howard J A standardized kinesin nomenclature J Cell Biol 2004 167 1 19 22 10.1083/jcb.200408113 15479732
Lawrence CJ, Dawe RK, Christie KR, Cleveland DW, Dawson SC, Endow SA, Goldstein LS, Goodson HV, Hirokawa N, Howard J, et al. A standardized kinesin nomenclature. J Cell Biol. 2004;167(1):19–22.15479732 10.1083/jcb.200408113
4. Verhey KJ Dishinger J Kee HL Kinesin motors and primary cilia Biochem Soc Trans 2011 39 5 1120 5 10.1042/BST0391120 21936775
Verhey KJ, Dishinger J, Kee HL. Kinesin motors and primary cilia. Biochem Soc Trans. 2011;39(5):1120–5.21936775 10.1042/BST0391120
5. Hirokawa N Tanaka Y Kinesin superfamily proteins (KIFs): various functions and their relevance for important phenomena in life and diseases Exp Cell Res 2015 334 1 16 25 10.1016/j.yexcr.2015.02.016 25724902
Hirokawa N, Tanaka Y. Kinesin superfamily proteins (KIFs): various functions and their relevance for important phenomena in life and diseases. Exp Cell Res. 2015;334(1):16–25.25724902 10.1016/j.yexcr.2015.02.016
6. Dagenbach EM Endow SA A new kinesin tree J Cell Sci 2004 117 Pt 1 3 7 10.1242/jcs.00875 14657268
Dagenbach EM, Endow SA. A new kinesin tree. J Cell Sci. 2004;117(Pt 1):3–7.14657268 10.1242/jcs.00875
7. Ruiz-Reig N Chehade G Hakanen J Aittaleb M Wierda K De Wit J Nguyen L Gailly P Tissir F KIF2A deficiency causes early-onset neurodegeneration Proc Natl Acad Sci U S A 2022 119 46 e2209714119 10.1073/pnas.2209714119 36343267
Ruiz-Reig N, Chehade G, Hakanen J, Aittaleb M, Wierda K, De Wit J, Nguyen L, Gailly P, Tissir F. KIF2A deficiency causes early-onset neurodegeneration. Proc Natl Acad Sci U S A. 2022;119(46):e2209714119.36343267 10.1073/pnas.2209714119
8. Nakano J Chiba K Niwa S An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity Genes Cells 2022 27 6 421 35 10.1111/gtc.12936 35430760
Nakano J, Chiba K, Niwa S. An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity. Genes Cells. 2022;27(6):421–35.35430760 10.1111/gtc.12936
9. Pant DC Parameswaran J Rao L Loss I Chilukuri G Parlato R Shi L Glass JD Bassell GJ Koch P ALS-linked KIF5A ∆Exon27 mutant causes neuronal toxicity through gain-of-function EMBO Rep 2022 23 8 e54234 10.15252/embr.202154234 35735139
Pant DC, Parameswaran J, Rao L, Loss I, Chilukuri G, Parlato R, Shi L, Glass JD, Bassell GJ, Koch P, et al. ALS-linked KIF5A ∆Exon27 mutant causes neuronal toxicity through gain-of-function. EMBO Rep. 2022;23(8):e54234.35735139 10.15252/embr.202154234
10. Serra-Marques A Martin M Katrukha EA Grigoriev I Peeters CA Liu Q Hooikaas PJ Yao Y Solianova V Smal I Concerted action of kinesins KIF5B and KIF13B promotes efficient secretory vesicle transport to microtubule plus ends Elife 2020 9 e61302 10.7554/eLife.61302 33174839
Serra-Marques A, Martin M, Katrukha EA, Grigoriev I, Peeters CA, Liu Q, Hooikaas PJ, Yao Y, Solianova V, Smal I, et al. Concerted action of kinesins KIF5B and KIF13B promotes efficient secretory vesicle transport to microtubule plus ends. Elife. 2020;9:e61302.33174839 10.7554/eLife.61302
11. Leong SY Edzuka T Goshima G Yamada M Kinesin-13 and Kinesin-8 function during cell growth and division in the moss physcomitrella patens Plant Cell 2020 32 3 683 702 10.1105/tpc.19.00521 31919299
Leong SY, Edzuka T, Goshima G, Yamada M. Kinesin-13 and Kinesin-8 function during cell growth and division in the Moss Physcomitrella patens. Plant Cell. 2020;32(3):683–702.31919299 10.1105/tpc.19.00521
12. Lin Y Wei YL She ZY Kinesin-8 motors: regulation of microtubule dynamics and chromosome movements Chromosoma 2020 129 2 99 110 10.1007/s00412-020-00736-7 32417983
Lin Y, Wei YL, She ZY. Kinesin-8 motors: regulation of microtubule dynamics and chromosome movements. Chromosoma. 2020;129(2):99–110.32417983 10.1007/s00412-020-00736-7
13. Gao T Yu L Fang Z Liu J Bai C Li S Xue R Zhang L Tan Z Fan Z KIF18B promotes tumor progression in osteosarcoma by activating β-catenin Cancer Biol Med 2020 17 2 371 86 10.20892/j.issn.2095-3941.2019.0452 32587775
Gao T, Yu L, Fang Z, Liu J, Bai C, Li S, Xue R, Zhang L, Tan Z, Fan Z. KIF18B promotes tumor progression in osteosarcoma by activating β-catenin. Cancer Biol Med. 2020;17(2):371–86.32587775 10.20892/j.issn.2095-3941.2019.0452
14. Lee YM Kim E Park M Moon E Ahn SM Kim W Hwang KB Kim YK Choi W Kim W Cell cycle-regulated expression and subcellular localization of a kinesin-8 member human KIF18B Gene 2010 466 1–2 16 25 20600703
Lee YM, Kim E, Park M, Moon E, Ahn SM, Kim W, Hwang KB, Kim YK, Choi W, Kim W. Cell cycle-regulated expression and subcellular localization of a kinesin-8 member human KIF18B. Gene. 2010;466(1–2):16–25.20600703
15. Li Q Sun M Meng Y Feng M Wang M Chang C Dong H Bu F Xu C Liu J Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma Oncogenesis 2023 12 1 54 10.1038/s41389-023-00499-7 37957153
Li Q, Sun M, Meng Y, Feng M, Wang M, Chang C, Dong H, Bu F, Xu C, Liu J, et al. Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma. Oncogenesis. 2023;12(1):54.37957153 10.1038/s41389-023-00499-7
16. Xie J Wang B Luo W Li C Jia X Upregulation of KIF18B facilitates malignant phenotype of esophageal squamous cell carcinoma by activating CDCA8/mTORC1 pathway J Clin Lab Anal 2022 36 10 e24633 10.1002/jcla.24633 36085568
Xie J, Wang B, Luo W, Li C, Jia X. Upregulation of KIF18B facilitates malignant phenotype of esophageal squamous cell carcinoma by activating CDCA8/mTORC1 pathway. J Clin Lab Anal. 2022;36(10):e24633.36085568 10.1002/jcla.24633
17. Ke H Wu S Zhang Y Zhang G miR-139-3p/Kinesin family member 18B axis suppresses malignant progression of gastric cancer Bioengineered 2022 13 2 4528 36 10.1080/21655979.2022.2033466 35137670
Ke H, Wu S, Zhang Y, Zhang G. miR-139-3p/Kinesin family member 18B axis suppresses malignant progression of gastric cancer. Bioengineered. 2022;13(2):4528–36.35137670 10.1080/21655979.2022.2033466
18. Wu YP Ke ZB Zheng WC Chen YH Zhu JM Lin F Li XD Chen SH Cai H Zheng QS Kinesin family member 18B regulates the proliferation and invasion of human prostate cancer cells Cell Death Dis 2021 12 4 302 10.1038/s41419-021-03582-2 33753726
Wu YP, Ke ZB, Zheng WC, Chen YH, Zhu JM, Lin F, Li XD, Chen SH, Cai H, Zheng QS, et al. Kinesin family member 18B regulates the proliferation and invasion of human prostate cancer cells. Cell Death Dis. 2021;12(4):302.33753726 10.1038/s41419-021-03582-2
19. Hong B Lu R Lou W Bao Y Qiao L Hu Y Liu K Chen J Bao D Ye M KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer Exp Cell Res 2021 407 2 112827 10.1016/j.yexcr.2021.112827 34508743
Hong B, Lu R, Lou W, Bao Y, Qiao L, Hu Y, Liu K, Chen J, Bao D, Ye M, et al. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer. Exp Cell Res. 2021;407(2):112827.34508743 10.1016/j.yexcr.2021.112827
20. Li B Liu B Zhang X Liu H He L KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8 J Cell Physiol 2020 235 5 4227 38 10.1002/jcp.29201 31875977
Li B, Liu B, Zhang X, Liu H, He L. KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8. J Cell Physiol. 2020;235(5):4227–38.31875977 10.1002/jcp.29201
21. Qiu MJ Zhang L Chen YB Zhu LS Zhang B Li QT Yang SL Xiong ZF KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma Int J Biochem Cell Biol 2021 137 106037 10.1016/j.biocel.2021.106037 34217812
Qiu MJ, Zhang L, Chen YB, Zhu LS, Zhang B, Li QT, Yang SL, Xiong ZF. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. Int J Biochem Cell Biol. 2021;137:106037.34217812 10.1016/j.biocel.2021.106037
22. Stout JR Yount AL Powers JA Leblanc C Ems-McClung SC Walczak CE Kif18B interacts with EB1 and controls astral microtubule length during mitosis Mol Biol Cell 2011 22 17 3070 80 10.1091/mbc.e11-04-0363 21737685
Stout JR, Yount AL, Powers JA, Leblanc C, Ems-McClung SC, Walczak CE. Kif18B interacts with EB1 and controls astral microtubule length during mitosis. Mol Biol Cell. 2011;22(17):3070–80.21737685 10.1091/mbc.e11-04-0363
23. McHugh T Gluszek AA Welburn JPI Microtubule end tethering of a processive kinesin-8 motor Kif18b is required for spindle positioning J Cell Biol 2018 217 7 2403 16 10.1083/jcb.201705209 29661912
McHugh T, Gluszek AA, Welburn JPI. Microtubule end tethering of a processive kinesin-8 motor Kif18b is required for spindle positioning. J Cell Biol. 2018;217(7):2403–16.29661912 10.1083/jcb.201705209
24. Luessing J Sakhteh M Sarai N Frizzell L Tsanov N Ramberg KO Maretto S Crowley PB Lowndes NF The nuclear kinesin KIF18B promotes 53BP1-mediated DNA double-strand break repair Cell Rep 2021 35 13 109306 10.1016/j.celrep.2021.109306 34192545
Luessing J, Sakhteh M, Sarai N, Frizzell L, Tsanov N, Ramberg KO, Maretto S, Crowley PB, Lowndes NF. The nuclear kinesin KIF18B promotes 53BP1-mediated DNA double-strand break repair. Cell Rep. 2021;35(13):109306.34192545 10.1016/j.celrep.2021.109306
25. Shrestha S Ems-McClung SC Hazelbaker MA Yount AL Shaw SL Walczak CE Importin α/β promote Kif18B microtubule association and enhance microtubule destabilization activity Mol Biol Cell 2023 34 4 ar30 10.1091/mbc.E22-03-0113 36790918
Shrestha S, Ems-McClung SC, Hazelbaker MA, Yount AL, Shaw SL, Walczak CE. Importin α/β promote Kif18B microtubule association and enhance microtubule destabilization activity. Mol Biol Cell. 2023;34(4):ar30.36790918 10.1091/mbc.E22-03-0113
26. Halasi M Gartel AL Targeting FOXM1 in cancer Biochem Pharmacol 2013 85 5 644 52 10.1016/j.bcp.2012.10.013 23103567
Halasi M, Gartel AL. Targeting FOXM1 in cancer. Biochem Pharmacol. 2013;85(5):644–52.23103567 10.1016/j.bcp.2012.10.013
27. Zhang L Zhu G Wang X Liao X Huang R Huang C Huang P Zhang J Wang P Genome–wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma Oncol Rep 2019 42 3 1017 34 31322267
Zhang L, Zhu G, Wang X, Liao X, Huang R, Huang C, Huang P, Zhang J, Wang P. Genome–wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma. Oncol Rep. 2019;42(3):1017–34.31322267
28. Wu Y Wang A Zhu B Huang J Lu E Xu H Xia W Dong G Jiang F Xu L KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer Onco Targets Ther 2018 11 1707 20 10.2147/OTT.S157440 29636620
Wu Y, Wang A, Zhu B, Huang J, Lu E, Xu H, Xia W, Dong G, Jiang F, Xu L. KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer. Onco Targets Ther. 2018;11:1707–20.29636620 10.2147/OTT.S157440
29. Jiang J Liu T He X Ma W Wang J Zhou Q Li M Yu S Silencing of KIF18B restricts proliferation and invasion and enhances the chemosensitivity of breast cancer via modulating Akt/GSK-3β/β-catenin pathway BioFactors 2021 47 5 754 67 10.1002/biof.1757 34058791
Jiang J, Liu T, He X, Ma W, Wang J, Zhou Q, Li M, Yu S. Silencing of KIF18B restricts proliferation and invasion and enhances the chemosensitivity of breast cancer via modulating Akt/GSK-3β/β-catenin pathway. BioFactors. 2021;47(5):754–67.34058791 10.1002/biof.1757
30. Ji Z Pan X Shang Y Ni DT Wu FL KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma Tissue Cell 2019 61 44 50 10.1016/j.tice.2019.09.001 31759406
Ji Z, Pan X, Shang Y, Ni DT, Wu FL. KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma. Tissue Cell. 2019;61:44–50.31759406 10.1016/j.tice.2019.09.001
31. Zhang W Liu Z MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway Pharmacogenet Genomics 2023 33 1 1 9 10.1097/FPC.0000000000000485 36441170
Zhang W, Liu Z. MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway. Pharmacogenet Genomics. 2023;33(1):1–9.36441170 10.1097/FPC.0000000000000485
32. Liu L Zhang Z Xia X Lei J KIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathway Oncol Lett 2022 23 4 112 10.3892/ol.2022.13232 35251343
Liu L, Zhang Z, Xia X, Lei J. KIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathway. Oncol Lett. 2022;23(4):112.35251343 10.3892/ol.2022.13232
33. Shin Y Du Y Collier SE Ohi MD Lang MJ Ohi R Biased brownian motion as a mechanism to facilitate nanometer-scale exploration of the microtubule plus end by a kinesin-8 Proc Natl Acad Sci U S A 2015 112 29 E3826 3835 10.1073/pnas.1500272112 26150501
Shin Y, Du Y, Collier SE, Ohi MD, Lang MJ, Ohi R. Biased brownian motion as a mechanism to facilitate nanometer-scale exploration of the microtubule plus end by a kinesin-8. Proc Natl Acad Sci U S A. 2015;112(29):E3826–3835.26150501 10.1073/pnas.1500272112
34. Welburn JP The molecular basis for kinesin functional specificity during mitosis Cytoskeleton  2013 70 9 476 93 10.1002/cm.21135 24039047
Welburn JP. The molecular basis for kinesin functional specificity during mitosis. Cytoskeleton  2013;70(9):476–93.24039047 10.1002/cm.21135
35. Walczak CE Zong H Jain S Stout JR Spatial regulation of astral microtubule dynamics by Kif18B in PtK cells Mol Biol Cell 2016 27 20 3021 30 10.1091/mbc.e16-04-0254 27559136
Walczak CE, Zong H, Jain S, Stout JR. Spatial regulation of astral microtubule dynamics by Kif18B in PtK cells. Mol Biol Cell. 2016;27(20):3021–30.27559136 10.1091/mbc.e16-04-0254
36. McHugh T Welburn JPI Potent microtubule-depolymerizing activity of a mitotic Kif18b-MCAK-EB network J Cell Sci 2023 136 5 jcs260144 10.1242/jcs.260144 35502670
McHugh T, Welburn JPI. Potent microtubule-depolymerizing activity of a mitotic Kif18b-MCAK-EB network. J Cell Sci. 2023;136(5):jcs260144.35502670 10.1242/jcs.260144
37. Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 6 394 424 10.3322/caac.21492 30207593
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593 10.3322/caac.21492
38. Chen B Zeng C Ye Y Wu D Mu Z Liu J Xie Y Wu H Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer J Cell Commun Signal 2018 12 2 423 32 10.1007/s12079-017-0418-2 29086202
Chen B, Zeng C, Ye Y, Wu D, Mu Z, Liu J, Xie Y, Wu H. Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer. J Cell Commun Signal. 2018;12(2):423–32.29086202 10.1007/s12079-017-0418-2
39. Bade BC Dela Cruz CS Lung cancer 2020: epidemiology, etiology, and prevention Clin Chest Med 2020 41 1 1 24 10.1016/j.ccm.2019.10.001 32008623
Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and Prevention. Clin Chest Med. 2020;41(1):1–24.32008623 10.1016/j.ccm.2019.10.001
40. Zhong Y Jiang L Long X Zhou Y Deng S Lin H Li X Clinical significance and integrative analysis of kinesin family member 18B in lung adenocarcinoma Onco Targets Ther 2019 12 9249 64 10.2147/OTT.S227438 31807007
Zhong Y, Jiang L, Long X, Zhou Y, Deng S, Lin H, Li X. Clinical significance and Integrative Analysis of Kinesin Family Member 18B in Lung Adenocarcinoma. Onco Targets Ther. 2019;12:9249–64.31807007 10.2147/OTT.S227438
41. Zhu Y Cao F Liu F Liu S Meng L Gu L Zhao H Sang M Shan B Identification of potential circular RNA biomarkers in lung adenocarcinoma: a bioinformatics analysis and retrospective clinical study Oncol Lett 2022 23 5 144 10.3892/ol.2022.13264 35340554
Zhu Y, Cao F, Liu F, Liu S, Meng L, Gu L, Zhao H, Sang M, Shan B. Identification of potential circular RNA biomarkers in lung adenocarcinoma: a bioinformatics analysis and retrospective clinical study. Oncol Lett. 2022;23(5):144.35340554 10.3892/ol.2022.13264
42. Lenis AT Lec PM Chamie K Mshs MD Bladder cancer: a review JAMA 2020 324 19 1980 91 10.1001/jama.2020.17598 33201207
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: a review. JAMA. 2020;324(19):1980–91.33201207 10.1001/jama.2020.17598
43. Dobruch J Oszczudłowski M Bladder cancer: current challenges and future directions Med  2021 57 8 749
Dobruch J, Oszczudłowski M. Bladder cancer: current challenges and future directions. Med  2021;57(8):749.
44. Walcher L Kistenmacher AK Suo H Kitte R Dluczek S Strauß A Blaudszun AR Yevsa T Fricke S Kossatz-Boehlert U Cancer Stem cells-origins and biomarkers: perspectives for targeted personalized therapies Front Immunol 2020 11 1280 10.3389/fimmu.2020.01280 32849491
Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U. Cancer Stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280.32849491 10.3389/fimmu.2020.01280
45. Pan S Zhan Y Chen X Wu B Liu B Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices Front Oncol 2019 9 613 10.3389/fonc.2019.00613 31334127
Pan S, Zhan Y, Chen X, Wu B, Liu B. Identification of biomarkers for Controlling Cancer Stem Cell characteristics in bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices. Front Oncol. 2019;9:613.31334127 10.3389/fonc.2019.00613
46. Yu S Han R Gan R The Wnt/β-catenin signalling pathway in haematological neoplasms Biomark Res 2022 10 1 74 10.1186/s40364-022-00418-9 36224652
Yu S, Han R, Gan R. The Wnt/β-catenin signalling pathway in Haematological Neoplasms. Biomark Res. 2022;10(1):74.36224652 10.1186/s40364-022-00418-9
47. Gilles H Garbutt T Landrum J Hepatocellular carcinoma Crit Care Nurs Clin North Am 2022 34 3 289 301 10.1016/j.cnc.2022.04.004 36049848
Gilles H, Garbutt T, Landrum J. Hepatocellular Carcinoma. Crit Care Nurs Clin North Am. 2022;34(3):289–301.36049848 10.1016/j.cnc.2022.04.004
48. Nagaraju GP Dariya B Kasa P Peela S El-Rayes BF Epigenetics in hepatocellular carcinoma Semin Cancer Biol 2022 86 Pt 3 622 32 10.1016/j.semcancer.2021.07.017 34324953
Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol. 2022;86(Pt 3):622–32.34324953 10.1016/j.semcancer.2021.07.017
49. Alawyia B Constantinou C Hepatocellular Carcinoma: a narrative review on current knowledge and future prospects Curr Treat Options Oncol 2023 24 7 711 24 10.1007/s11864-023-01098-9 37103744
Alawyia B, Constantinou C. Hepatocellular Carcinoma: a narrative review on current knowledge and future prospects. Curr Treat Options Oncol. 2023;24(7):711–24.37103744 10.1007/s11864-023-01098-9
50. Yang B Wang S Xie H Wang C Gao X Rong Y Liu Z Lu Y KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway J Cell Physiol 2020 235 10 6507 14 10.1002/jcp.29444 32052444
Yang B, Wang S, Xie H, Wang C, Gao X, Rong Y, Liu Z, Lu Y. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway. J Cell Physiol. 2020;235(10):6507–14.32052444 10.1002/jcp.29444
51. Li X Huang W Huang W Wei T Zhu W Chen G Zhang J Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma Am J Transl Res 2020 12 5 1614 39 32509165
Li X, Huang W, Huang W, Wei T, Zhu W, Chen G, Zhang J. Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma. Am J Transl Res. 2020;12(5):1614–39.32509165
52. Li R Cui X Sun W Yang Z Shen X Zhu C ASF1B, as an independent prognostic biomarker, correlates with Immune infiltrates in hepatocellular carcinoma Comb Chem High Throughput Screen 2023 26 7 1311 23 10.2174/1386207325666220820112111 35993469
Li R, Cui X, Sun W, Yang Z, Shen X, Zhu C. ASF1B, as an independent Prognostic Biomarker, correlates with Immune infiltrates in Hepatocellular Carcinoma. Comb Chem High Throughput Screen. 2023;26(7):1311–23.35993469 10.2174/1386207325666220820112111
53. Tang S Wu Z Chen L She L Zuo W Luo W Zhang Y Liang S Liu G He B Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma Front Immunol 2023 14 1258344 10.3389/fimmu.2023.1258344 37744335
Tang S, Wu Z, Chen L, She L, Zuo W, Luo W, Zhang Y, Liang S, Liu G, He B, et al. Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma. Front Immunol. 2023;14:1258344.37744335 10.3389/fimmu.2023.1258344
54. Saleiro D Platanias LC Intersection of mTOR and STAT signaling in immunity Trends Immunol 2015 36 1 21 9 10.1016/j.it.2014.10.006 25592035
Saleiro D, Platanias LC. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015;36(1):21–9.25592035 10.1016/j.it.2014.10.006
55. Guri Y Nordmann TM Roszik J mTOR at the transmitting and receiving ends in tumor immunity Front Immunol 2018 9 578 10.3389/fimmu.2018.00578 29662490
Guri Y, Nordmann TM, Roszik J. mTOR at the transmitting and receiving ends in Tumor Immunity. Front Immunol. 2018;9:578.29662490 10.3389/fimmu.2018.00578
56. Grabinski VF Brawley OW Disparities in breast cancer Obstet Gynecol Clin North Am 2022 49 1 149 65 10.1016/j.ogc.2021.11.010 35168767
Grabinski VF, Brawley OW. Disparities in breast Cancer. Obstet Gynecol Clin North Am. 2022;49(1):149–65.35168767 10.1016/j.ogc.2021.11.010
57. Corti C Giugliano F Nicolò E Tarantino P Criscitiello C Curigliano G HER2-low breast cancer: a new subtype? Curr Treat Options Oncol 2023 24 5 468 78 10.1007/s11864-023-01068-1 36971965
Corti C, Giugliano F, Nicolò E, Tarantino P, Criscitiello C, Curigliano G. HER2-Low breast Cancer: a New Subtype? Curr Treat Options Oncol. 2023;24(5):468–78.36971965 10.1007/s11864-023-01068-1
58. Li TF Zeng HJ Shan Z Ye RY Cheang TY Zhang YJ Lu SH Zhang Q Shao N Lin Y Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer Cancer Cell Int 2020 20 123 10.1186/s12935-020-01191-1 32322170
Li TF, Zeng HJ, Shan Z, Ye RY, Cheang TY, Zhang YJ, Lu SH, Zhang Q, Shao N, Lin Y. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell Int. 2020;20:123.32322170 10.1186/s12935-020-01191-1
59. Pastushenko I Blanpain C EMT transition states during tumor progression and metastasis Trends Cell Biol 2019 29 3 212 26 10.1016/j.tcb.2018.12.001 30594349
Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212–26.30594349 10.1016/j.tcb.2018.12.001
60. Pan G Liu Y Shang L Zhou F Yang S EMT-associated microRNAs and their roles in cancer stemness and drug resistance Cancer Commun  2021 41 3 199 217 10.1002/cac2.12138
Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun  2021;41(3):199–217.10.1002/cac2.12138
61. Suo HD Tao Z Zhang L Jin ZN Li XY Ma W Wang Z Qiu Y Jin F Chen B Coexpression network analysis of genes related to the characteristics of tumor stemness in triple-negative breast cancer Biomed Res Int 2020 2020 7575862 10.1155/2020/7575862 32766313
Suo HD, Tao Z, Zhang L, Jin ZN, Li XY, Ma W, Wang Z, Qiu Y, Jin F, Chen B, et al. Coexpression network analysis of genes related to the characteristics of tumor stemness in triple-negative breast cancer. Biomed Res Int. 2020;2020:7575862.32766313 10.1155/2020/7575862
62. Guan WL He Y Xu RH Gastric cancer treatment: recent progress and future perspectives J Hematol Oncol 2023 16 1 57 10.1186/s13045-023-01451-3 37245017
Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.37245017 10.1186/s13045-023-01451-3
63. Yang WJ Zhao HP Yu Y Wang JH Guo L Liu JY Pu J Lv J Updates on global epidemiology, risk and prognostic factors of gastric cancer World J Gastroenterol 2023 29 16 2452 68 10.3748/wjg.v29.i16.2452 37179585
Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, Pu J, Lv J. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452–68.37179585 10.3748/wjg.v29.i16.2452
64. Matsuoka T Yashiro M Novel biomarkers for early detection of gastric cancer World J Gastroenterol 2023 29 17 2515 33 10.3748/wjg.v29.i17.2515 37213407
Matsuoka T, Yashiro M. Novel biomarkers for early detection of gastric cancer. World J Gastroenterol. 2023;29(17):2515–33.37213407 10.3748/wjg.v29.i17.2515
65. Guo SH Ma L Chen J Identification of prognostic markers and potential therapeutic targets in gastric adenocarcinoma by machine learning based on mRNAsi Index J Oncol 2022 2022 8926127 10.1155/2022/8926127 36213825
Guo SH, Ma L, Chen J. Identification of prognostic markers and potential therapeutic targets in gastric adenocarcinoma by machine learning based on mRNAsi Index. J Oncol. 2022;2022:8926127.36213825 10.1155/2022/8926127
66. Chen X Zhang D Jiang F Shen Y Li X Hu X Wei P Shen X Prognostic prediction using a Stemness Index-Related signature in a cohort of gastric cancer Front Mol Biosci 2020 7 570702 10.3389/fmolb.2020.570702 33134315
Chen X, Zhang D, Jiang F, Shen Y, Li X, Hu X, Wei P, Shen X. Prognostic prediction using a Stemness Index-Related signature in a cohort of gastric Cancer. Front Mol Biosci. 2020;7:570702.33134315 10.3389/fmolb.2020.570702
67. Ishikawa A Yasumatsu R Fukui T Kido A Katsuya N Sentani K Kuraoka K Oue N Suzuki T Oka S Kinesin Family member B18 is related to gastric mucin phenotype and contributes to gastric cancer progression by regulating epithelial-mesenchymal transition Oncology 2024 102 4 354 65 10.1159/000533791 37812924
Ishikawa A, Yasumatsu R, Fukui T, Kido A, Katsuya N, Sentani K, Kuraoka K, Oue N, Suzuki T, Oka S, et al. Kinesin Family Member B18 is related to gastric mucin phenotype and contributes to Gastric Cancer Progression by regulating epithelial-mesenchymal transition. Oncology. 2024;102(4):354–65.37812924 10.1159/000533791
68. Xia X Li Y Comprehensive analysis of transcriptome data stemness indices identifies key genes for controlling cancer stem cell characteristics in gastric cancer Transl Cancer Res 2020 9 10 6050 61 10.21037/tcr-20-704 35117216
Xia X, Li Y. Comprehensive analysis of transcriptome data stemness indices identifies key genes for controlling cancer stem cell characteristics in gastric cancer. Transl Cancer Res. 2020;9(10):6050–61.35117216 10.21037/tcr-20-704
69. Huang C Hu CG Ning ZK Huang J Zhu ZM Identification of key genes controlling cancer stem cell characteristics in gastric cancer World J Gastrointest Surg 2020 12 11 442 59 10.4240/wjgs.v12.i11.442 33304447
Huang C, Hu CG, Ning ZK, Huang J, Zhu ZM. Identification of key genes controlling cancer stem cell characteristics in gastric cancer. World J Gastrointest Surg. 2020;12(11):442–59.33304447 10.4240/wjgs.v12.i11.442
70. Yang H Wang Y Zhang Z Li H Identification of KIF18B as a hub candidate gene in the metastasis of clear cell renal cell carcinoma by weighted gene co-expression network analysis Front Genet 2020 11 905 10.3389/fgene.2020.00905 32973873
Yang H, Wang Y, Zhang Z, Li H. Identification of KIF18B as a Hub Candidate Gene in the metastasis of clear cell renal cell carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet. 2020;11:905.32973873 10.3389/fgene.2020.00905
71. Liu W Yu Z Tang H Wang X Zhang B Zhao J Liu X Zhang J Wei M Silencing KIF18B enhances radiosensitivity: identification of a promising therapeutic target in sarcoma EBioMedicine 2020 61 103056 10.1016/j.ebiom.2020.103056 33038765
Liu W, Yu Z, Tang H, Wang X, Zhang B, Zhao J, Liu X, Zhang J, Wei M. Silencing KIF18B enhances radiosensitivity: identification of a promising therapeutic target in sarcoma. EBioMedicine. 2020;61:103056.33038765 10.1016/j.ebiom.2020.103056
72. Yan H Zhu C Zhang L Kinesin family member 18B: a contributor and facilitator in the proliferation and metastasis of cutaneous melanoma J Biochem Mol Toxicol 2019 33 12 e22409 10.1002/jbt.22409 31617652
Yan H, Zhu C, Zhang L. Kinesin family member 18B: a contributor and facilitator in the proliferation and metastasis of cutaneous melanoma. J Biochem Mol Toxicol. 2019;33(12):e22409.31617652 10.1002/jbt.22409
73. Davis AJ Tsinkevich M Rodencal J Abbas HA Su XH Gi YJ Fang B Rajapakshe K Coarfa C Gunaratne PH TAp63-Regulated miRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell-cycle genes Cancer Res 2020 80 12 2484 97 10.1158/0008-5472.CAN-19-1892 32156775
Davis AJ, Tsinkevich M, Rodencal J, Abbas HA, Su XH, Gi YJ, Fang B, Rajapakshe K, Coarfa C, Gunaratne PH, et al. TAp63-Regulated miRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell-cycle genes. Cancer Res. 2020;80(12):2484–97.32156775 10.1158/0008-5472.CAN-19-1892
74. Xiong J Zhang J Li H Identification of G2 and S phase-Expressed-1 as a potential biomarker in patients with prostate cancer Cancer Manag Res 2020 12 9259 69 10.2147/CMAR.S272795 33061616
Xiong J, Zhang J, Li H. Identification of G2 and S phase-Expressed-1 as a potential biomarker in patients with prostate Cancer. Cancer Manag Res. 2020;12:9259–69.33061616 10.2147/CMAR.S272795
75. Zhao H Yu J Zhang R Chen P Jiang H Yu W Doxorubicin prodrug-based nanomedicines for the treatment of cancer Eur J Med Chem 2023 258 115612 10.1016/j.ejmech.2023.115612 37441851
Zhao H, Yu J, Zhang R, Chen P, Jiang H, Yu W. Doxorubicin prodrug-based nanomedicines for the treatment of cancer. Eur J Med Chem. 2023;258:115612.37441851 10.1016/j.ejmech.2023.115612
76. Peter S Alven S Maseko RB Aderibigbe BA Doxorubicin-based hybrid compounds as potential anticancer agents: a review Molecules 2022 27 14 4478 10.3390/molecules27144478 35889350
Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-based hybrid compounds as potential anticancer agents: a review. Molecules. 2022;27(14):4478.35889350 10.3390/molecules27144478
77. Shafei A El-Bakly W Sobhy A Wagdy O Reda A Aboelenin O Marzouk A El Habak K Mostafa R Ali MA A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer Biomed Pharmacother 2017 95 1209 18 10.1016/j.biopha.2017.09.059 28931213
Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, Marzouk A, El Habak K, Mostafa R, Ali MA, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209–18.28931213 10.1016/j.biopha.2017.09.059
78. Browne IM André F Chandarlapaty S Carey LA Turner NC Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer Lancet Oncol 2024 25 4 e139 51 10.1016/S1470-2045(23)00676-9 38547898
Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25(4):e139–51.38547898 10.1016/S1470-2045(23)00676-9
79. Kang L Tian Y Xu S Chen H Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment J Neurol 2021 268 9 3269 82 10.1007/s00415-020-09942-w 32474658
Kang L, Tian Y, Xu S, Chen H. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol. 2021;268(9):3269–82.32474658 10.1007/s00415-020-09942-w
80. Li Y Gan Y Liu J Li J Zhou Z Tian R Sun R Liu J Xiao Q Li Y Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer Signal Transduct Target Ther 2022 7 1 87 10.1038/s41392-022-00902-6 35351858
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, Sun R, Liu J, Xiao Q, Li Y, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87.35351858 10.1038/s41392-022-00902-6
81. Rovsing AB Thomsen EA Nielsen I Skov TW Luo Y Dybkaer K Mikkelsen JG Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28 Br J Haematol 2023 202 4 825 39 10.1111/bjh.18872 37190875
Rovsing AB, Thomsen EA, Nielsen I, Skov TW, Luo Y, Dybkaer K, Mikkelsen JG. Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. Br J Haematol. 2023;202(4):825–39.37190875 10.1111/bjh.18872
82. Gan LH Yao L Yan JH Huang YQ Zheng L Liu P Lei L Differential expression of KIF18B in gastric cancer and its role in chemotherapy sensitivity Crit Rev Eukaryot Gene Expr 2024 34 3 37 48 10.1615/CritRevEukaryotGeneExpr.2023049523 38305287
Gan LH, Yao L, Yan JH, Huang YQ, Zheng L, Liu P, Lei L. Differential expression of KIF18B in gastric Cancer and its role in Chemotherapy Sensitivity. Crit Rev Eukaryot Gene Expr. 2024;34(3):37–48.38305287 10.1615/CritRevEukaryotGeneExpr.2023049523
83. Zhou Z Guan B Xia H Zheng R Xu B Particle radiotherapy in the era of radioimmunotherapy Cancer Lett 2023 567 216268 10.1016/j.canlet.2023.216268 37331583
Zhou Z, Guan B, Xia H, Zheng R, Xu B. Particle radiotherapy in the era of radioimmunotherapy. Cancer Lett. 2023;567:216268.37331583 10.1016/j.canlet.2023.216268
84. Hoefkens F Dehandschutter C Somville J Meijnders P Van Gestel D Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy Radiat Oncol 2016 11 1 136 10.1186/s13014-016-0668-9 27733179
Hoefkens F, Dehandschutter C, Somville J, Meijnders P, Van Gestel D. Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy. Radiat Oncol. 2016;11(1):136.27733179 10.1186/s13014-016-0668-9
